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The most frequent and severe complications after chimeric antigen receptor T-cells (CAR-T cells) therapy include cytokine release 
syndrome (CRS), immune effector cell‐associated neurotoxicity syndrome (ICANS), macrophage activation syndrome/hemophagocytic 
lymphohistiocytosis (MAS/HLH), tumor lysis syndrome (TLS), followed by B-cell aplasia and hypogammaglobulinemia. With these 
immunologically related events, cytokine storm and immunosuppression, there is a high risk of sepsis and infectious complications. The 
objective of this review was to present current knowledge on incidence, risk factors, clinical characteristics, and outcome of infections 
in patients following CAR-T cells therapy, as well as to present current recommendations on prophylaxis of infections after CAR-T cells 
therapy. Comparable to hematopoietic cell transplantation setting, specific pre- and post-CAR-T cells infusion phases can be determined 
as early (from 0 to +30 days), intermediate (from +31 to +100 days), and late (beyond day +100). These phases are characterized by 
CAR-T cells therapy-related factors and immune system defects contributing to an increased risk of infections. It is recommended that 
in case of active infection, CAR-T cells infusion should be delayed until infection has been successfully treated. After CAR-T cells therapy, 
prophylaxis should be implemented (anti-bacterial, anti-viral, anti-fungal, anti-pneumocystis), as well as treatment of neutropenia 
and immunoglobulin replacement should be considered. No recommendations so far can be given on revaccinations after CAR-T cells 
therapy.
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Introduction
Chimeric antigen receptor T-cells (CAR-T cells) are a new cancer 
treatment modality for certain B-cell malignancies [1]. Adoptive 
immunotherapy with the use of CAR-T cells targeted against CD19-
positive cells has been successful in producing durable remissions 
in patients with relapsed or refractory acute lymphocyte leukemia 
and non-Hodgkin’s lymphoma (NHL) [2–6]. CAR-T cells are a form of 
autologous immunotherapy that already has changed the therapeutic 
landscape of some B-cell hematologic malignancies. Principles of 
CAR-T cells therapy involve initial collection of a patient’s T cells by 
apheresis and then ex vivo genetic modification of the T-cells to encode 
a synthetic receptor that binds a specific antigen of malignant cells, 
followed by infusion of the modified T-cells back to the patient.
From the clinical point of view and procedures that need to be done, 
this therapeutic technology is somehow comparable to hematopoietic 
cell transplantation (HCT). It seems that both CAR-T cells and HCT as 
forms of cellular therapy are, and will be, of great value for patients. 
Although relatively excellent outcome has been shown for patients 
treated with CAR-T cells for relapsed or refractory B-cell malignancies, 
there are many issues to be solved, both in terms of remission of 
primary disease and complications during therapy. CAR-T cells therapy 
is a potentially curative treatment but is associated with life-threatening 
toxicities and can require long-term local follow-up evaluations and 
restrictions.
The most frequent and severe complications after CAR-T cells 
therapy include cytokine release syndrome (CRS), immune effector 
cell-associated neurotoxicity syndrome (ICANS), macrophage 
activation syndrome/hemophagocytic lymphohistiocytosis (MAS/
HLH), tumor lysis syndrome (TLS), followed by B cell aplasia and 
hypogammaglobulinemia [2–7]. With these immunologically related 
events, cytokine storm and immunosuppression, there is a high risk of 
sepsis and infectious complications.
This review was aimed to present current knowledge on incidence, 
risk factors, clinical characteristics, and outcome of infections in 
patients following CAR-T cells therapy, as well as to present current 
recommendations on prevention of infections after CAR-T cells therapy.
Phases post CAR-T cells therapy
With respect to predictable immunosuppression and the risk of 
opportunistic infections, the post-HCT period is usually divided 
into three phases: early (from 0 to +30 days), intermediate (from 
+31 to +100 days), and late (beyond day +100). These phases are 
characterized by immune system defects (neutropenia, lymphopenia, 
and hypogammaglobulinemia) and transplant-related factors (central 
venous access line, mucositis, and syndromes of epithelial damage) 
contributing to increased risk of infections. Comparable to HCT setting, 
specific pre- and post-CAR-T cells infusion phases can be determined 
(Fig. 1), although their characteristics can vary significantly.
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Risk factors for infections
Up to the end of 2019, only a few studies dedicated to infections after 
CAR-T cells therapy have been published [8-12]. All major studies 
on CAR-T cells therapy report adverse events including infectious 
complications.
Predisposing factors for infections after CAR-T cells therapy include 
primary disease (such as acute lymphoblastic leukemia (ALL) and 
NHL), primary disease-related immunodeficiency resulting in heavy 
pretreatment of patients (with most patients receiving at least four prior 
chemotherapy regimens, ranging up to 11 lines, and 38% of patients 
being post allo-HCT or auto-HCT), conditioning of lymphodepleting 
therapy before CAR-T cells infusion (most often regimen of 
cyclophosphamide+fludarabine is used, leading to cytopenia and 
prolonged cellular immunodeficiency), neutropenia (usual duration is 
one week, although 37% cytopenias are unresolved yet by day 28, 
and 15–35% patients develop febrile neutropenia), severe toxicities 
such as CRS/ICANS and their treatment with immunosuppressive 
drugs (corticosteroids and/or tocilizumab), B cells aplasia and 
hypogammaglobulinemia, and intensive care unit (ICU) admission 
[3, 4, 13–16].
Severity of CRS corresponds to serum cytokine profile, including 
interferon gamma, interleukin-2, interleukin-10, interleukin-15, 
and tumor necrosis factor alpha; however, no differences between 
patients with CRS with and without infections were found [9]. The 
use of tocilizumab (anti-IL-6 monoclonal antibody) in the treatment 
of CRS can be a potential risk factor for serious bacterial infections, 
nocardial infections, skin and soft tissue infections, diverticulitis, viral 
reactivation, and tuberculosis [3, 4, 13, 14, 15].
In the study of Hill et al., risk factors for infection after CAR-T cells 
infusion in univariate analysis included higher CAR-T cells dose (with 
two cutoff values: 2 × 106/kg and 2 × 107/kg), more severe CRS or 
neurotoxicity, and ICU treatment. In multivariate analysis, the only 
significant risk factor for infection after CAR-T cells infusion was the 
severity of CRS [8].
Incidence and clinical characteristics of infections
Two US studies reported on infectious complications following 
CAR-T cells therapy for ALL, CLL, and NHL during Phase 1/2 studies, 
which followed after 53 and 133 patients had relapsed or refractory 
malignancies for 3 months in one study and for 6 months in another 
study, respectively [8, 9]. The incidence of infectious complications 
was 23–42% in the first month after CAR-T cells therapy and 14–
31% later. These studies have shown that respectively 38% and 
42% of all infections occur between 30 and 100 days after CAR-T 
cells infusion [8, 9]. Severe co-infections occurring with CRS include 
community-acquired respiratory virus (CARV) infections, including 
also nosocomial infections; cytomegalovirus (CMV) infections; HHV-6 
infections; EBV infections; Clostridium difficile colitis; cholangitis; and 
viral encephalitis [4, 17, 18, 19].
The first infection was identified at a median of 6 (1–27) days after 
CAR-T cells infusion, with 80% of first infectious episodes occurring 
during first 10 days, including Gram-negative bacterial infections 
often with antimicrobial resistance. Bacterial infections were the most 
common (17%), followed by viral infections (8%), mainly caused by 
respiratory viruses. Incidence of infection between 30 and 90 days 
was much lower, with viral infections being the most common. 
During this period, B cell depletion was seen in 98% of patients 
Figure 1. Phases of predictable immune suppression and infections after CAR-T cel therapy
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and hypogammaglobulinemia (IgG<0.4 g/L) was detected in 46% 
patients up to 90 days. Nevertheless, during this period, persistent 
disease was still present in 42% patients and neutropenia in 22% 
patients, what could contribute to infectious episodes. Most of the 
infections during the period between 0 and 90 days after CAR-T cells 
infusion were mild or moderate, and life-threatening or fatal infections 
were infrequent [8].
Infectious complications occurred in 23–42% patients during the 
first month after CAR-T cells infusion, including an incidence of 
17% bacterial infections (bloodstream in 8–13% and bacterial site 
in 9–17%), 8% viral infections (respiratory virus in 6–7% and other 
viruses in 2–4%), and 3–6% fungal infections (yeasts 2% and mold 
2–6%), although 9.5–10% of patients received antifungal prophylaxis 
[8, 9].
Median time to infection by organism type was 18 days (bacterial 
infections), 23 days (fungal infections), and 48 days (viral infections). 
Viral infections were the most common infection type among late 
infections (>30 days) in both studies. Most infections are seen within 
the first 30 days and are bacterial and, to a lesser extent, respiratory 
viral infections. Invasive fungal infections are rare and are mostly 
observed in ALL patients who have undergone prior allogeneic 
HCT. So far 10 cases of invasive mold disease (mainly invasive 
aspergillosis) have been described in the literature [8, 9, 11, 12].
Beyond day +100, there is still low risk of late infections. Risk 
factors include frequent hypogammaglobulinemia and prolonged 
neutropenia (in 16% of patients). Most infections in this phase are 
mild and treated in the outpatient setting [10].
Infection density
Infection densities were calculated as the mean number of infections 
for every 100 patient days [8]. Infection density was significantly 
higher in the first month after treatment, as compared to the later 
period. Infection density was 1.19 (at 0–28 days) and 0.67 (at 29–
90 days) (p=0.02).
Analysis of severity of infections following CAR-T cells therapy 
showed that half of infections were mild to moderate and 41% were 
severe, 6% were life-threatening, and 3% were fatal infections. 
Overall, five patients in both studies died due to infections, four due 
to bacterial infections and one due to aspergillosis [8, 9].
Factors association with infection density: diagnosis of ALL, ≥4 prior 
antitumor regimens, receipt of the highest CAR-T cells dose, and 
the severity of CRS (grades 4–5 vs grades 1–3 vs grade 0) were 
associated with higher infection density within 28 days. Patients 
receiving a treatment regimen optimized to reduce the severity of 
CRS had fewer and less severe infections after CAR-T cells infusion 
compared with patients not receiving an optimized regimen [8]. These 
predictors of infection and bloodstream infection were confirmed in 
another study: CRS grade ≥3 was associated with an increased risk 
for any infection, with the highest risk of bacteremia [9].
With respect to infection density in the intermediate phase, mild 
infections required no treatment, moderate infections required 
oral treatment only, and severe infections required intravenous 
antimicrobial therapy or were associated with other clinical 
circumstances that were considered severe, with the exception of 
bacteremia due to possible skin contaminants and fever without 
systemic symptoms (categorized as moderate). Life-threatening 
infections were complicated by symptoms considered as life-
threatening [8].
Prophylaxis of infections
Before CAR-T cells therapy
The decision of treatment with a CAR-T cells therapy should be 
based on medical history, physical condition, and the current status 
of the patient. Among factors that are important in determining 
patient suitability for treatment are analysis of infectious profile and 
requirement to rule out ongoing infection. Active infections must 
be ruled out before starting lymphodepleting (LD) conditioning [6]. 
LD is contra-indicated in patients with active infection. Relative 
contra-indication should be estimated on individualized risk–
benefit assessment. Active infection should be controlled on 
treatment prior to leukapheresis. Checklist of laboratory tests prior 
to conditioning can be useful including C-reactive protein (CRP), 
alanine aminotransferase (ALAT), and aspartate aminotransferase 
(ASPAT). Infectious conditions that should be ruled out include active 
or latent hepatitis B or hepatitis C (test within 8 weeks of screening) 
or any uncontrolled infection at screening (ELIANA Kymriah, ALL 
study) [4]; uncontrolled active or latent hepatitis B or active hepatitis 
C or uncontrolled acute life-threatening bacterial, viral, or fungal 
infection, e.g., positive blood cultures <72 hours prior to screening 
(JULIET, Kymriah, DLBCL study) [15]; known history of HIV, hepatitis 
B (HepBsAg positive), or hepatitis C (anti-HCV); clinically significant 
active infection; or currently receiving IV antibiotics within 7 days of 
enrollment (ZUMA-1, Yescarta, NHL study) [5]. CAR-T cells infusion 
should be delayed until active infection has been successfully treated.
Active infections should be fully treated prior to the administration of 
LD conditioning and the infusion of CAR-T cells products, especially 
given the likely cytokine-driven exacerbation of inflammatory 
processes.
The presence of fever should prompt blood and urine cultures, and 
a chest radiograph. Depending on symptoms, screening for CARV, 
CMV, and EBV nucleic acid testing (NAT) should be performed. 
Chest/abdominal CT imaging, brain MRI, and/or lumbar puncture 
should be considered if necessary. Empirical antimicrobial therapy 
based on signs and symptoms, as well as local institutional protocols, 
should be implemented based on the anticipation of CRS and 
neutropenia [6].
Early phase
At the early phase, approximately one-third of patients receiving 
CAR-T cells therapy have prolonged neutropenia beyond day +30 
including up to 20% of patients who have neutropenia for more than 
90 days. Additional risk factors for infections involve B-cell depletion 
and hypogammaglobulinemia [3, 4].
CAR-T cells recipients are at an increased risk of infections at the 
different stages of their treatment, which identifies a targeted group 
for prophylactic strategies. Since infections are one of the most 
common complications, an appropriate antimicrobial prophylaxis 
is required after CAR-T cells therapy, especially with respect to 
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antibacterial prophylaxis, as it is the most common infective problem 
in the early phase. Strategies established in other setting could be 
adopted to prevent infection after CAR-T cells therapy. Prophylactic 
anti-infective approach should be based on respective regimens in 
patients undergoing allo-HCT. The summary of European Society for 
Blood and Marrow Transplantation (EBMT) prophylactic anti-infective 
recommendations is presented in table I [6].
Viral infections seem to be of a lower significance in the early 
phase. So far there are no evidences that CMV, EBV, or ADV might 
be a significant clinical problem after CAR-T cells therapy. No data 
are available about the risk of HBV/HCV reactivation, neither HIV 
infection, as these patients are excluded from the trials. Still, for 
patients with a history of HBV infection, prophylaxis with tenofovir 
should be recommended.
Intermediate term (between day +30 and day +100) com-
plications and management
Majority of patients face prolonged or late B-cell aplasia and 
hypogammaglobulinemia. Both factors might significantly contribute 
to infectious complications. Neutropenia, thrombocytopenia, and 
anemia are common at this stage; however, these conditions slowly 
resolve over next several months. Sometimes support with growth 
factor may be indicated in the early stages.
During this phase, patients should be monitored for full blood count, 
renal and liver biochemistry panel, LDH, ferritin, fibrinogen, CRP, 
quantitative immunoglobulin, and serum protein electrophoresis 
at every visit, as well as peripheral blood immunophenotyping for 
CD3/4/8/16+56/19 and CAR-T cells monitoring where commercial 
kits are available for routine monitoring of anti-CD19 CAR-T cells (if 
necessary) once a month. Polymerase chain reaction (PCR) for viral 
reactivation (CMV, EBV, adenovirus) in peripheral blood should be 
done, if clinically indicated [6].
Patients should be monitored for prolonged cytopenia, disease 
remission, and secondary malignancies. Prophylaxis and treatment 
of infection and immunoglobulin monitoring and supplementation 
should be strongly considered, especially in the pediatric setting. 
B-cell aplasia can be used as a pharmacodynamic measure of the 
persistence of functional CD19-targeted T cells (CAR-T cells). The 
probability of relapse-free B-cell aplasia at 6 months was 73%. 
Continued B-cell aplasia was seen in all patients who had a sustained 
remission, and none of the patients with B-cell aplasia had a CD19-
positive relapse [3, 4].
During this period, B-cell aplasia and hypogammaglobulinemia 
are two major risk factors for infectious complications. Prolonged 
B-cell aplasia beyond day +30 after CAR-T cells infusion is an 
almost universal on-target, off-tumor toxicity. It obviously results in 
hypogammaglobulinemia, occurs in almost all responding patients 
and persists even for up to one year [8]. Additionally, lymphopenia 
might occur [8]. B-cell aplasia can serve as a marker for monitoring 
presence of CD19-specific CAR-T cells activity over time.
At this phase, viral infections usually predominate including 
respiratory viral infections, as well as CMV viremia and pneumonia, 
and BK polyoma virus cystitis. Sinopulmonary infections, usually 
with encapsulated bacteria, might also occur. One might consider 
specific vaccination, but no evidence is available so far. Pediatric 
centers usually prefer immunoglobulin replacement following use of 
CAR-T cells in order to maintain IgG levels ≥0.4 g/L, regardless of 
time requirement.
Long-term follow-up
The common requirement in 2019 for new studies on CAR-T 
cells therapy was a long-term follow-up, even up to 15 years post 
CAR-T cells infusion, in order to estimate clinical condition, immune 
reconstitution, and remission status. Recommended tests to be 
performed include full blood count, biochemistry panel, quantitative 
immunoglobulin, and serum protein electrophoresis, as well as 
CAR-T cells monitoring where commercial kits are available for 
routine monitoring of anti-CD19 CAR-T cells (if necessary) at every 
visit, peripheral blood immunophenotyping for CD3/4/8/16+56/19 
every second visit, and endocrine function and other standard late 
Table I. Anti-infective prophylaxis after CAR-T cells therapy 
Prophylaxis Recommendation Comment
Antibacterial Not routine; in patients with neutropenic 
fever, empiric treatment with broad spectrum 
antibiotics is strongly recommended
Management should be based on local guidelines (e.g., with levofloxacin or 
ciprofloxacin)
Antiviral Acyclovir 2 × 800 mg (in children 2 × 20 mg/kg) or 
valaciclovir 2 × 500 mg
Start from LD conditioning until one year post CAR-T cells therapy and/or until 
CD4+ count >0.2 × 109/L
Antifungal Not routine; however, consider if patient is 
neutropenic and on corticosteroids
In patients with prior allo-HCT, prior invasive aspergillosis and those receiving 
corticosteroids, posaconazole prophylaxis is recommended
Anti-pneumocystis Co-trimoxazole 480 mg once daily or 960 mg 
three times each week
Start from LD conditioning until one year post CAR-T cells infusion and/or until 
CD4+ count >0.2 × 109/L. Alternatively, pentamidine inhalation (300 mg once 
every month), dapsone 100 mg, or atovaquone 1500 mg once daily
Neutropenia Not routine; however, consider if patient has 
severe infections in neutropenia
Avoid if patient has or had CRS (G-CSF can trigger CRS) or neurotoxicity
Immunoglobulin 
replacement
Routine IVIG in children (to keep >0.4 g/L) and in 
adults who have had infections with encapsulated 
organisms
Clinical evidence does not support routine use in adults following allo-HCT
General remark: it is advised to adhere to national or local guidelines or standard practice. G-CSF –  granulocyte colony stimulating factor; CRS – cytokine release 
syndrome; LD – lymphodepleting; allo-HCT – allogeneic hematopoietic cell transplantation; CAR-T cells – chimeric antigen receptor T-cell; IVIG – intravenous 
immunoglobulin.
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effects testing appropriate to age – yearly or as clinically indicated. 
Additionally, peripheral blood PCR tests for viral reactivation should 
be performed, when clinically indicated [6].
Vaccination issues
Live vaccines are contraindicated 6 weeks prior to CAR-T cells 
therapy. Since there are no data regarding revaccination, no 
recommendations can be given for patients after CAR-T cells therapy; 
however, Center for Disease Control and Prevention (CDC) suggests 
HCT-like protocol. Previous oncologic therapy, immunosuppressive 
lymphodepletion, and anti B cell properties of CAR-T cells therapy 
probably fully abolish effects of previous immunization. On the other 
hand, antigen-specific IgG antibodies may be produced by long-lived 
plasma cells not expressing CD19, so that preexisting antibodies 
may persist in CAR-T cells recipients. Thus, the existence of memory 
B-cell-independent, long-lived plasma cells in humans can contribute 
to long-lasting humoral immunity [20].
The role of vaccinations following CAR-T cells therapy is not known 
yet. Owing to lack of evidence, no specific recommendations can be 
made. This is particularly an important problem for small children 
who have not yet completed their mandatory immunization schedule. 
Therefore, this group of patients need special and close follow-up.
Recent analysis has shown that humoral immunity as detected by 
VirScan assay to some viruses (e.g., measles) may be maintained 
or even recover after successful anti-CD19 CAR-T cells therapy 
in adults; however, there are no data available for children [21]. In 
general, it is recommended that if vaccines are given, response with 
specific antibody should be assessed. Anticipating long-term B cell 
depletion, it is advised that adherence to the recommended standard 
national vaccination schedules should be individualized based on the 
history of previous vaccinations, previous infections, and laboratory 
assessments of humoral and cellular immunity [7].
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